Compare Ascendis Pharma A/S (ASND) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs EPAM Systems Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while EPAM Systems Inc trades at $84.52 (market cap $4.38B). The key difference: Ascendis Pharma A/S is far larger — about 4.1× EPAM Systems Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| ASND | EPAM | |
|---|---|---|
Market Cap | $17.74B | $4.38B |
Sector | Health | Technology |
52-Week High | $277.18 | $221.40 |
52-Week Low | $163.32 | $76.04 |
Enterprise Value | $18.11B | $3.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EPAM Systems trades at $83.89, down 3.9% in the last session, with a bearish technical signal from moving averages. The company maintains solid profitability with 29% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights EPAM's AI partnerships and upcoming Q2 2026 earnings release. Valuation metrics appear attractive with P/E of 12.05 and P/S of 0.84, well below sector averages.
The stock presents a compelling value opportunity with strong analyst support (65% buy ratings) and a $128.55 consensus price target representing 53% upside potential. Key risks include competitive pressures in IT services and recent net income margin compression from 9.61% in 2024 to 6.96% in 2025. The upcoming Q2 earnings report on July 6, 2026 will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
